Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer



Status:Not yet recruiting
Conditions:Colorectal Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:19 - Any
Updated:2/22/2019
Start Date:April 2019
End Date:January 2026
Contact:Suzanne Lapi, PhD
Email:lapi@uab.edu
Phone:205-975-8689

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for
imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node
involvement. If promising, this data will be used to design larger trials.


Inclusion Criteria:

- Be at least 19 years of age.

- Diagnosis of colon cancer

- Scheduled to undergo surgical resection

Exclusion Criteria:

- Inability to provide informed consent

- Pregnancy

- Inability to lie still for the imaging study

- Weight over 350 lbs., due to the scanner bore size

- Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)

- Inability to receive Omnipaque (iohexol) iodinated contrast

- Inability to receive glucagon

- Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent

- Allergy to contrast imaging agents

- Finding or suspicion of distant metastases on CT
We found this trial at
1
site
UAB Advanced Imaging Facility
619 19th Street South
Birmingham, Alabama 35294
?
mi
from
Birmingham, AL
Click here to add this to my saved trials